What was the major announcement from Entropy Neurodynamics (ASX:ENP)?

Entropy Neurodynamics filed US Provisional Patent Application No. 64/055,765 to protect new clinical insights regarding its IBS treatment program. The filing is underpinned by Phase 2a data showing a 75% response rate in patients with treatment-resistant irritable bowel syndrome.

How did the Phase 2a clinical results for TRP-8802 compare to existing IBS treatments?

The Phase 2a study for TRP-8802 (oral psilocybin) delivered a 75% response rate, significantly outperforming current standard therapies which typically see 17–44% efficacy. Researchers from Harvard Medical School and Columbia University described this as the strongest clinical signal ever reported in IBS drug development.

What is the significance of the US patent filing for Entropy Neurodynamics (ASX:ENP)?

The US filing expands the company’s patent families beyond its existing Australian protections, which already cover precision-controlled psilocybin delivery through 2042.

What is TRP-8803 and how does it fit into the company's strategy?

TRP-8803 is Entropy’s lead asset, consisting of an IV-infused psilocin treatment designed to address nociplastic pain and psychological disorders. The new patent filing directly supports the development of TRP-8803 by providing a clinical-data-driven foundation for its use in treating gut-brain interactions.

Why is the "gut-brain" disorder market important for ASX:ENP investors?

The gut-brain market is considered a large and underserved sector, representing a significant commercial opportunity for biotechnology companies. Entropy is positioning itself as a specialist in this niche by targeting treatment-resistant patients who have failed existing therapies.

What are the primary risks associated with Entropy Neurodynamics (ASX:ENP) right now?

As a clinical-stage biotech with a share price of $0.036, the company remains highly speculative and subject to significant regulatory risk. While the Phase 2a data is strong, the US patent is currently only a "provisional application," meaning full grant and protection are not guaranteed.

Entropy advances IBS treatment with new US patent

Written by Liezl GambePublished May. 5 2026Last Updated May. 5 2026

Clinical-stage biotechnology firm Entropy Neurodynamics (ASX:ENP) announced a step forward in its mission to tackle treatment-resistant irritable bowel syndrome with the filing of US Provisional Patent Application No. 64/055,765.

The move aims to solidify the company's foothold in the lucrative "gut-brain" disorder market by leveraging groundbreaking Phase 2a clinical data.

Presented at Digestive Disease Week 2026 by researchers from Massachusetts General Hospital and Columbia University, the study revealed a remarkable 75% response rate among patients who had previously failed traditional therapies.

The figure dwarfs the 17–44% efficacy typically seen in current IBS treatments, marking what experts describe as the strongest clinical signal ever reported in the field's history.

The new filing strengthens Entropy’s global intellectual property portfolio, complementing an existing Australian patent that protects their precision-controlled psilocybin and psilocin delivery methods through 2042.

By securing these rights, Entropy is not only enhancing its long-term exclusivity but also streamlining its US-focused development and partnering strategy for its lead asset, TRP-8803.

The IV-infused psilocin treatment represents a novel approach to nociplastic pain and psychological disorders, bridging the gap between mental health and gastrointestinal care.

At the time of reporting, Entropy Neurodynamics’ share price was $0.036.